Deutsche Bank Remains a Hold on Sanofi (SNYNF)
Top Gap Ups and Downs on Monday: SNY, GFI, LI and More
Top HHS Spokesman Tom Corry Abrupty Resigns
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Is Sanofi (SNY) The Best Immunology Stock To Buy Now?
Sanofi and Teva Reveal Promising Duvakitug Study Results at ECCO 2025
Media Update: AAD: New Data Advance Sanofi's Scientific Leadership Across Innovative Treatments for Inflammatory Skin Diseases
Sanofi India Reports Strong Financial Results and Proposes Dividend
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax Stock Rises as Revenue Beat Estimates
Novavax Posts Q4 Revenue Beat Despite 80% Drop in Product Sales
FDA AdCom Meeting on Flu Vaccines Canceled
Sanofi's Sustained Revenue Growth Potential: Buy Rating Justified by Extended Amvuttra Royalties
CDC A(H5N1) Bird Flu Response Update February 26, 2025; Confirmed 3 Human Cases Of H5 Bird Flu In People Who Became Ill In 2025 - Website
U.S. to Spend up to $1B for Bird Flu Response
Scribe Therapeutics to Participate in Upcoming Conferences
Enveda Gains Backing From Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
Sanofi Target Raised to EUR125 From EUR100 by Intron Health
Sanofi Raised to Buy From Hold by Intron Health
Duvakitug, co-developed by Sanofi (SNY.US) and Teva (TEVA.US), is expected to enter phase 3 clinical trials in the second half of the year.
Sanofi (SNY.US) and Teva (TEVA.US) recently announced the detailed results obtained from their jointly developed monoclonal antibody duvakitug in the phase 2 clinical trial RELIEVE UCCD.